Abstract

Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pro-inflammatory cytokine that is increased in the amniotic fluid in chorioamnionitis and elevated in the fetal lung with endotoxin exposure. Although GM-CSF has a pivotal role in fetal lung development, it stimulates pulmonary macrophages and is associated with the development of bronchopulmonary dysplasia (BPD). How antenatal GM-CSF results in recruitment of lung macrophage leading to BPD needs further elucidation. Hence, we used a transgenic and knock-out mouse model to study the effects of GM-CSF focusing on the fetal lung macrophage.Methods: Using bitransgenic (BTg) mice that conditionally over-expressed pulmonary GM-CSF after doxycycline treatment, and GM-CSF knock-out (KO) mice with no GM-CSF expression, we compared the ontogeny and immunophenotype of lung macrophages in BTg, KO and control mice at various prenatal and postnatal time points using flow cytometry and immunohistology.Results: During fetal life, compared to controls, BTg mice over-expressing pulmonary GM-CSF had increased numbers of lung macrophages that were CD68+ and these were primarily located in the interstitium rather than alveolar spaces. The lung macrophages that accumulated were predominantly CD11b+F4/80+ indicating immature macrophages. Conversely, lung macrophages although markedly reduced, were still present in GM-CSF KO mice.Conclusion: Increased exposure to GM-CSF antenatally, resulted in accumulation of immature macrophages in the fetal lung interstitium. Absence of GM-CSF did not abrogate but delayed the transitioning of interstitial macrophages. Together, these results suggest that other perinatal factors may be involved in modulating the maturation of alveolar macrophages in the developing fetal lung.

Highlights

  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein which was discovered as a hemopoietic growth factor based on its ability to stimulate bone marrow cell proliferation in a mouse lung-conditioned medium [1]

  • We confirmed the non-inducible GM-CSF expression in the WT and single transgenic (STg) littermates showing no differences in the percentages of positive F4/80 and CD11b cells on flow cytometry or CD68 positive macrophages on lung immunohistology after Dox treatment at E16.5 and E18.5 (Supplementary Figure 1)

  • Switching on with Dox resulted in markedly increased GM-CSF in bronchoalveolar lavage fluid (BALF) of bi-transgenic mice (BTg), E18.5 fetal mice

Read more

Summary

Introduction

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein which was discovered as a hemopoietic growth factor based on its ability to stimulate bone marrow cell proliferation in a mouse lung-conditioned medium [1]. Augmentation of GM-CSF resulted in the proliferation of type II alveolar epithelial cells, restoration of alveolar epithelial barrier function, increased vascular endothelial growth factor expression, enhancement of lung growth and surfactant phospholipid production in several animal models, suggesting the role of this cytokine in the lung reparative and remodeling process [5, 10,11,12]. These may underlie clinical observations of a lesser burden of respiratory distress syndrome in preterm infants with intrauterine exposure to chorioamnionitis [13,14,15]. We used a transgenic and knock-out mouse model to study the effects of GM-CSF focusing on the fetal lung macrophage

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call